Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Deferred Taxes (2016 - 2018)

Niagen Bioscience (NAGE) has disclosed Deferred Taxes for 6 consecutive years, with -$16000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Deferred Taxes fell 100.0% to -$16000.0 in Q4 2018 year-over-year; TTM through Sep 2019 was -$16000.0, a 260.0% decrease, with the full-year FY2018 number at $2000.0, down 98.89% from a year prior.
  • Deferred Taxes was -$16000.0 for Q4 2018 at Niagen Bioscience, down from -$8000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $321037.0 in Q4 2016 to a low of -$50000.0 in Q1 2018.
  • A 3-year average of $50227.5 and a median of -$8000.0 in 2017 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: skyrocketed 1081.37% in 2016, then plummeted 225.0% in 2018.
  • Niagen Bioscience's Deferred Taxes stood at $321037.0 in 2016, then tumbled by 102.49% to -$8000.0 in 2017, then tumbled by 100.0% to -$16000.0 in 2018.
  • Per Business Quant, the three most recent readings for NAGE's Deferred Taxes are -$16000.0 (Q4 2018), -$8000.0 (Q3 2018), and $76000.0 (Q2 2018).